| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 790-798, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
S Bosari, G Viale, M Roncalli, D Graziani, G Borsani, AK Lee and G Coggi
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8020, USA.
p53 accumulation may occur in the nucleus and/or cytoplasm of neoplastic cells. Cytoplasmic accumulation has been reported to be an unfavorable, but not established, prognostic indicator in colorectal cancer. Different types of p53 intracellular compartmentalization could depend either on p53 gene mutations or on the interaction with p53 protein ligands. The purposes of our study were (1) to assess whether the different patterns of p53 accumulation are selectively associated with p53 mutations and (2) to evaluate the clinical significance of p53 mutations in colorectal carcinomas. We evaluated p53 gene mutations in colorectal carcinomas. We evaluated p53 gene mutations in exons 5 through 8, by polymerase chain reaction and single-strand conformation polymorphism analysis; p53 accumulation and intracellular compartmentalization were detected immunocytochemically with the antibodies PAb1801 and CM1. p53 mutations were found in 74 of 126 carcinomas (59%). Nuclear p53PAb1801 accumulation was associated with p53 gene mutations (P < 0.001) whereas cytoplasmic p53 CM1 accumulation was more likely to occur with the wild-type p53 gene (P = 0.048). Overall, 112 carcinomas (89%) displayed p53 gene mutations and/or p53 accumulations of any type. p53 mutations were not correlated with important clinicopathological parameters and were not related to patient survival. Our data suggest that mechanisms other than mutations may also play a role in inhibiting p53 tumor-suppressing functions in colorectal carcinomas. Cytoplasmic p53CM1 accumulation frequently does not depend on p53 mutations.
This article has been cited by other articles:
 |
|
 |
|
  D. Das, K. Wojno, and M. J. Imperiale BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages J. Virol., March 15, 2008; 82(6): 2705 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamamoto, T. Ozaki, M. Nakanishi, H. Kikuchi, K. Yoshida, H. Horie, H. Kuwano, and A. Nakagawara Oxidative stress induces p53-dependent apoptosis in hepatoblastoma cell through its nuclear translocation Genes Cells, April 1, 2007; 12(4): 461 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsubochi, N. Sato, M. Hiyama, M. Kaimori, S. Endo, Y. Sohara, and T. Imai Combined Analysis of Cyclooxygenase-2 Expression With p53 and Ki-67 in Nonsmall Cell Lung Cancer. Ann. Thorac. Surg., October 1, 2006; 82(4): 1198 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Kaul, S. Aida, T. Yaguchi, K. Kaur, and R. Wadhwa Activation of Wild Type p53 Function by Its Mortalin-binding, Cytoplasmically Localizing Carboxyl Terminus Peptides J. Biol. Chem., November 25, 2005; 280(47): 39373 - 39379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Russo, V. Bazan, B. Iacopetta, D. Kerr, T. Soussi, N. Gebbia, and for the TP53-CRC Collaborative Study Group The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment J. Clin. Oncol., October 20, 2005; 23(30): 7518 - 7528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mueller, B. W. Schafer, S. Ferrari, M. Weibel, M. Makek, M. Hochli, and C. W. Heizmann The Calcium-binding Protein S100A2 Interacts with p53 and Modulates Its Transcriptional Activity J. Biol. Chem., August 12, 2005; 280(32): 29186 - 29193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Garrity, L. J. Burgart, M. R. Mahoney, H. E. Windschitl, M. Salim, M. Wiesenfeld, J. E. Krook, J. C. Michalak, R. M. Goldberg, M. J. O'Connell, et al. Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study J. Clin. Oncol., May 1, 2004; 22(9): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Facchetti, D. Uberti, M. Memo, and C. Missale Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase Mol. Endocrinol., January 1, 2004; 18(1): 162 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Swamy, C. R. Herzog, and C. V. Rao Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53 Cancer Res., September 1, 2003; 63(17): 5239 - 5242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Chen, J. L. Merchant, P. B. S. Lai, R. L. K. Ho, X. Hu, M. Okada, S. F. Huang, A. K. K. Chui, D. J. Law, Y. G. Li, et al. Mutation of p53 in Recurrent Hepatocellular Carcinoma and Its Association with the Expression of ZBP-89 Am. J. Pathol., June 1, 2003; 162(6): 1823 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Du, G. G. Chen, A. C. Vlantis, H. Xu, R. K.Y. Tsang, and A. C. van Hasselt The Nuclear Localization of NF{kappa}B and p53 Is Positively Correlated with HPV16 E7 Level in Laryngeal Squamous Cell Carcinoma J. Histochem. Cytochem., April 1, 2003; 51(4): 533 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Moos, K. Edes, P. Cassidy, E. Massuda, and F. A. Fitzpatrick Electrophilic Prostaglandins and Lipid Aldehydes Repress Redox-sensitive Transcription Factors p53 and Hypoxia-inducible Factor by Impairing the Selenoprotein Thioredoxin Reductase J. Biol. Chem., January 3, 2003; 278(2): 745 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Russo, M. Migliavacca, I. Zanna, M. R. Valerio, M. A. Latteri, N. Grassi, G. Pantuso, S. Salerno, G. Dardanoni, I. Albanese, et al. p53 Mutations in L3-Loop Zinc-binding Domain, DNA-Ploidy, and S Phase Fraction Are Independent Prognostic Indicators in Colorectal Cancer: A Prospective Study with a Five-Year Follow-Up Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1322 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Grassme, J. Bock, J. Kun, and E. Gulbins Clustering of CD40 Ligand Is Required to Form a Functional Contact with CD40 J. Biol. Chem., August 9, 2002; 277(33): 30289 - 30299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Houlston What we could do now: molecular pathology of colorectal cancer Mol. Pathol., August 1, 2001; 54(4): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Forslund, C. Lonnroth, M. Andersson, H. Brevinge, and K. Lundholm Mutations and Allelic Loss of p53 in Primary Tumor DNA From Potentially Cured Patients With Colorectal Carcinoma J. Clin. Oncol., June 1, 2001; 19(11): 2829 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Liang and M. F. Clarke A Bipartite Nuclear Localization Signal Is Required for p53 Nuclear Import Regulated by a Carboxyl-terminal Domain J. Biol. Chem., November 12, 1999; 274(46): 32699 - 32703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zaika, N. Marchenko, and U. M. Moll Cytoplasmically "Sequestered" Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation J. Biol. Chem., September 24, 1999; 274(39): 27474 - 27480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tortola, E. Marcuello, I. Gonzalez, G. Reyes, R. Arribas, G. Aiza, F. J. Sancho, M. A. Peinado, and G. Capella p53 and K-ras Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1375 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Liang, D. Hong, and M. F. Clarke Cooperation of a Single Lysine Mutation and a C-terminal Domain in the Cytoplasmic Sequestration of the p53 Protein J. Biol. Chem., July 31, 1998; 273(31): 19817 - 19821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Rayanade, M. I. Ndubuisi, J. D. Etlinger, and P. B. Sehgal Regulation of IL-6 Signaling by p53: STAT3- and STAT5-Masking in p53-Val135-Containing Human Hepatoma Hep3B Cell Lines J. Immunol., July 1, 1998; 161(1): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-K. Hwang and C.-T. Lin Co-localization of Endogenous and Exogenous p53 Proteins in Nasopharyngeal Carcinoma Cells J. Histochem. Cytochem., July 1, 1997; 45(7): 991 - 1004. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. G. Ostermeyer, E. Runko, B. Winkfield, B. Ahn, and U. M. Moll Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide PNAS, December 24, 1996; 93(26): 15190 - 15194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akakura, M. Yoshida, Y. Yoneda, and S. Horinouchi A Role for Hsc70 in Regulating Nucleocytoplasmic Transport of a Temperature-sensitive p53 (p53Val-135) J. Biol. Chem., April 27, 2001; 276(18): 14649 - 14657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-S. Kim, D.-H. Kim, S.-M. Han, M.-U. Chin, H.-J. Nam, H.-P. Cho, S.-Y. Choi, B.-J. Song, E.-R. Kim, Y.-S. Bae, et al. Truncated Form of Importin alpha Identified in Breast Cancer Cell Inhibits Nuclear Import of p53 J. Biol. Chem., July 21, 2000; 275(30): 23139 - 23145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Moos, K. Edes, and F. A. Fitzpatrick Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins PNAS, August 1, 2000; 97(16): 9215 - 9220. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
